Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease.
Brief Summary: The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy in participants with CD20+ (tumor-infiltrating lymphocytic) Malignant Disease, including B-cell chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). The primary objective for the phase II part of the study is to investigate the efficacy and safety of one dose of obinutuzumab in participants with relapsed/refractory CLL and NHL that is, in turn, either indolent (iNHL) or aggressive (aNHL).

It is an open label dose escalating study in phase I and open label in phase II, but the two doses in iNHL \& aNHL are randomized (to high or low dose of the same open label treatment). CLL was not randomized as only one dose level was used.

Participants with a response who might gain additional benefit from being treated again in the opinion of the investigator may be enrolled in a Retreatment Period.


Options:
A: Arm Label: Ofatumumab (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Drug: ofatumumab | Arm Label: ibrutinib (Arm B); Type: EXPERIMENTAL; Interventions: Drug: ibrutinib | Intervention Type: DRUG; Name: ofatumumab; Assigned to Arm(s): Ofatumumab (Arm A) | Intervention Type: DRUG; Name: ibrutinib; Assigned to Arm(s): ibrutinib (Arm B)
B: Arm Label: Bendamustine + Ofatumumab + Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Ofatumumab, Drug: Ibrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib
C: Arm Label: Treatment (alemtuzumab, rituximab, fludarabine phosphate); Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab, Biological: rituximab, Drug: fludarabine phosphate | Intervention Type: BIOLOGICAL; Name: alemtuzumab; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate) | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate) | Intervention Type: DRUG; Name: fludarabine phosphate; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate)
D: Arm Label: Phase I, NHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Phase I, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1000/1000 mg - Phase II, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Retreated Participants; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): 1000/1000 mg - Phase II, CLL, 1600/800 mg - Phase II, aNHL, 1600/800 mg - Phase II, iNHL, 400/400 mg - Phase II, aNHL, 400/400 mg - Phase II, iNHL, Phase I, CLL, Phase I, NHL, Retreated Participants

Answer: D